Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes

ERBB2 amplification is a prognostic marker for aggressive tumors and a predictive marker for prolonged survival following treatment with HER2 inhibitors. We attempt to sub-group HER2+ tumors based on amplicon structures and co-amplified genes. We examined five HER2+ cell lines, three HER2+ xenograph...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Sci Rep
Asıl Yazarlar: Maoz, Myriam, Devir, Michal, Inbar, Michal, Inbar-Daniel, Ziva, Sherill-Rofe, Dana, Bloch, Idit, Meir, Karen, Edelman, David, Azzam, Salah, Nechushtan, Hovav, Maimon, Ofra, Uziely, Beatrice, Kadouri, Luna, Sonnenblick, Amir, Eden, Amir, Peretz, Tamar, Zick, Aviad
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6906288/
https://ncbi.nlm.nih.gov/pubmed/31827209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-55455-6
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller